MRNA

Moderna closed an upsized $3.0B offering of zero-coupon convertible senior notes paired with capped calls to limit equity dilution.

The stock dropped 5.77% due to valuation-driven profit-taking after a massive rally sparked by Phase 3 cancer vaccine trial data.

Moderna shares surged due to Wall Street analyst upgrades and price target hikes following positive Phase 3 cancer trial results.

Moderna announced positive Phase 3 trial results for its personalized mRNA cancer vaccine combined with Keytruda in melanoma patients.

Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine in high-risk melanoma patients.

Moderna fell 23.55% on profit-taking and valuation resets after a 177% rally driven by Phase 3 cancer vaccine trial results.

Moderna announced positive Phase 3 trial data for its mRNA cancer vaccine combined with Keytruda in treating melanoma.

Moderna surged after FDA approval of its mRNA flu vaccine, a Q2 earnings beat, and a $200 million reduction in operating expenses.

Moderna stock surged due to FDA approval of its mRNA flu vaccine, a Q2 earnings beat, reduced expense guidance, and institutional buying.

Moderna shares surged after the FDA approved mFLUSIVA, the first mRNA-based seasonal influenza vaccine authorized in the U.S.

Moderna fell due to escalating patent litigation with Sanofi and CureVac, valuation concerns ahead of Q2 earnings, and insider selling.

Moderna fell due to Danaher's weak earnings dragging biotechs lower, pre-catalyst investor de-risking, and new patent litigation.

The stock fell due to Wall Street downgrades, pre-earnings de-risking, high valuation multiples, and a looming $950M settlement payment.

JPMorgan placed MRNA on its Top Short Ideas list due to valuation over-expansion, cash burn, and a missed flu contracting window.

The stock fell due to negative analyst notes from JPMorgan and Morgan Stanley alongside a $950 million patent settlement payout.

Moderna fell due to a JP Morgan Sell rating, slashed Q2 revenue guidance, and a $950 million patent settlement cash outflow.

Moderna fell due to a JPMorgan short call, lowered respiratory vaccine guidance, and a $950 million patent litigation payout.

JPMorgan reaffirmed its Sell rating on Moderna and added the stock to its Q3 2026 Tactical Short List.

Morgan Stanley reiterated a Neutral rating with a $39 price target, sparking profit-taking over valuation concerns.

The stock surged following a unanimous FDA advisory committee vote recommending approval for its mFlusiva seasonal mRNA flu vaccine.

The stock surged due to high FDA approval odds for its flu vaccine candidate mRNA-1010, pipeline updates, and an analyst upgrade.

Shares surged after a 9-0 FDA Advisory Committee vote backed its flu vaccine and a Science Day presentation revealed a new pipeline.

Moderna stock surged following a unanimous 9-0 FDA panel endorsement for its flu vaccine and a strategic Science Day pipeline presentation.